Cut through the noise, find the signal: Intelligence for serious healthcare leaders
Analysis updated November 9, 2026
ASM represents the most aggressive specialist accountability experiment CMMI has attempted since the cancelled Radiation Oncology Model. Its mandatory design — covering roughly one-quarter of all core-based statistical areas (CBSAs) and metropolitan divisions — eliminates the selection bias that plagued voluntary models and signals that the Trump administration's CMMI under Abe Sutton is comfortable with coercive enrollment when the clinical rationale is sufficiently targeted.
The condition selection is deliberate and defensible. Heart failure ($10–13 billion in annual Medicare spending) and low back pain ($6–8 billion) together represent $16–21 billion in annual Original Medicare expenditure — both characterized by high procedure intensity, weak evidence for many interventions, and demonstrable variation in specialist practice patterns. That combination makes them credible targets for performance-based payment adjustment. CMS is not testing whether value-based care works generically; it is testing whether financial accountability applied directly to the specialist ordering the MRI, the spinal fusion, or the IV diuretic changes behavior.
The payment architecture carries a distinctive structural choice: symmetric two-sided risk applied directly to Medicare Part B professional fees, not to an episode budget or shared savings pool. Payment adjustments run from -9% to +9% in performance years 1–2 (payments years 2029–2030), escalating to -12%/+12% by performance year 5 (payment year 2033). This means a cardiologist billing $500,000 annually in Part B professional services faces a maximum downside of $45,000 in year one and $60,000 by year five — applied as a multiplier to every covered service claim for an entire calendar year. Unlike episode-based models where risk is episodic and actuarially diversifiable, ASM's adjustment is a blanket percentage on total Part B volume. A bad performance year has no hedge.
The model uses a zero-sum cohort comparison structure: positive adjustments for high performers are explicitly calibrated not to exceed negative adjustments from low performers. This is budget-neutral by design. CMS is not offering net new money — it is redistributing existing Part B dollars within each cohort. High performers benefit only to the extent low performers underperform. This creates both an incentive to outperform peers and a structural ceiling on aggregate gains.
The CY 2027 PFS Final Rule introduced a rural scoring adjustment of 5 points — a relatively modest concession that acknowledges geographic care complexity without meaningfully altering the risk calculus for rural specialists who face thinner patient panels and less infrastructure for care coordination.
One underappreciated design risk: participant eligibility is reassessed annually using data from two years prior. A specialist who drops below 20 attributed episodes in a given calendar year could exit ASM in a subsequent performance year — losing MIPS waiver protection and reverting to standard MIPS reporting mid-model-cycle. For specialists near the 20-episode threshold, panel management becomes a compliance function.
Break-even framing for a mid-volume cardiologist:
Assume a cardiologist billing $400,000 annually in Medicare Part B professional fees with 25 attributed heart failure episodes. In performance year 1 (payment year 2029), the maximum downside is $36,000 (9% of $400,000). The maximum upside is $36,000. The expected value of participation is not neutral — it is slightly negative for below-median performers even before accounting for compliance infrastructure costs.
Compliance infrastructure investment:
For a small cardiology practice (≤15 NPIs), realistic first-year compliance costs are $15,000–$40,000 in operational investment (IT configuration, legal fees, staff training). For a large multispecialty group, per-physician marginal cost is lower but aggregate compliance overhead is substantial.
Failure-to-comply scenario: An ASM participant who fails to report at least one non-administrative-claims-based quality measure meeting 75% data completeness receives a final score of zero and the maximum negative payment adjustment — -9% in year one, -12% by year five. This is not a hypothetical edge case; it is the default outcome for any practice that treats ASM reporting as optional.
Best case (top-quartile performer, $600K Part B volume): +$54,000 annual adjustment in year one; +$72,000 by year five. Expected case (median performer): Neutral adjustment, net negative after compliance costs of roughly -$20,000 to -$35,000 annually. Worst case (bottom-quartile, non-reporting): -$54,000 to -$72,000 adjustment plus compliance costs — a total swing of $70,000–$110,000 versus top performers in the same cohort.
Large integrated delivery systems and multispecialty groups are structurally advantaged. They can amortize CCA legal infrastructure across dozens of TIN/NPI combinations, already have CEHRT platforms meeting PI requirements, and have existing PCP-specialist communication workflows that satisfy IA-1 and IA-2 with minimal new investment. Their scale also generates episode volumes well above the 20-episode minimum, ensuring consistent eligibility and score stability.
Independent and small-group specialists are most exposed. A solo interventional pain management physician in a mandatory CBSA who bills $250,000 in Part B faces a worst-case downside of $22,500 in year one and $30,000 by year five — amounts that are material relative to practice economics — without the shared infrastructure of a large system to absorb compliance costs. The small practice adjustment (10-point bonus for 2–15 NPI practices; 15-point bonus for solos) partially offsets this, but does not alter the fundamental asymmetry.
MSSP ACO participants have a critical advantage: ASM participants can remain in MSSP and receive shared savings distributions concurrently. For a cardiologist embedded in a high-performing ACO, ASM's care coordination requirements (CCA, PCP communication) may already be substantially satisfied by existing ACO infrastructure. The ACO's care management team can handle HRSN screening and transition planning, reducing marginal IA compliance cost toward zero.
Medicare Advantage plans are spectators with indirect exposure. ASM applies exclusively to Original Medicare (fee-for-service) beneficiaries. MA plans face no direct payment adjustment risk, but the model's behavioral effects — increased PCP-specialist communication, reduced procedural utilization, more structured referral pathways — may shift practice patterns that bleed into MA patient management. MA plans with large risk-bearing groups in mandatory CBSAs should monitor whether ASM-driven care redesign creates favorable spillover in their populations.
Market consolidation signal: Mandatory model pressure on independent specialists historically accelerates acquisition interest from health systems seeking to absorb practices and their compliance infrastructure. Expect acquisition multiples for affected cardiology and spine specialty groups in mandatory CBSAs to reflect ASM risk as a discount factor in near-term transactions.
Physicians: The core grievance will be loss of autonomy without commensurate risk-sharing infrastructure. A cardiologist selected into ASM has no opt-out, faces symmetric financial risk on Part B revenue, and must execute legally binding CCAs with primary care practices — relationships that require negotiation, ongoing documentation, and potential remuneration arrangements governed by Anti-Kickback safe harbor requirements (42 CFR § 1001.952(ii)). The specialty type redesignation exception — which allows heart failure cohort cardiologists who formally redesignate to cardiac electrophysiology, interventional cardiology, or related subspecialties to exit — will generate significant Medicare enrollment activity in mandatory CBSAs as affected physicians evaluate their options.
Health systems: ASM creates a new compliance and performance management obligation for employed specialists. CMOs must build performance reporting infrastructure for eCQM submission, track CCA execution across employed and affiliated physicians, and monitor episode-based cost measure performance to avoid cohort-relative underperformance. The 2-year payment lag (performance year 2027 → payment year 2029) means financial impact is deferred but permanent once it arrives — health system CFOs should model ASM adjustments into 2029 and beyond financial projections now.
Hospitals: Downstream implications are real but indirect. If ASM successfully reduces avoidable hospitalizations for heart failure and low back pain — the model's stated primary outcome — inpatient volume in mandatory CBSAs for these DRGs should decline. For health systems with high contribution margin on elective spine procedures and heart failure admissions, successful ASM implementation by affiliated specialists is financially adverse from a hospital revenue perspective, even as it may benefit the system's risk-bearing entities.
Payer/MA Plans: The model creates a natural experiment in specialist accountability that MA plans should track for plan design implications. If ASM demonstrates that performance-adjusted Part B payments reduce unnecessary lumbar MRIs and avoidable heart failure readmissions, MA plans will have actuarial evidence to redesign specialist network tiering and prior authorization thresholds accordingly. The model's enhanced data feedback to participants (episode-based cost, utilization, and quality data) creates a parallel information asymmetry: ASM participants will have detailed performance benchmarking that non-ASM specialists — including those treating MA patients — do not.
Bottom line: ASM is a structurally sound mandatory model with meaningful financial stakes and a realistic theory of change. The specialists with infrastructure — whether through health system employment or ACO integration — will treat it as manageable. Those without infrastructure face a genuine performance risk that cannot be managed through clinical excellence alone. Act on compliance readiness now; the model launched January 1, 2027, and payment adjustments hit Part B claims beginning January 1, 2029.